Amicus Therapeutics (FOLD) Misses Q3 EPS by 10c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. SPY
9. XYZ
10. CVS

Go back to Amicus Therapeutics (FOLD) Misses Q3 EPS by 10c

Amicus Therapeutics Announces Third Quarter 2017 Financial Results and Corporate Updates

November 8, 2017 7:00 AM EST

260+ Fabry Patients on Reimbursed Galafold (Migalastat) and On Target to Reach 300 Patients by Year-End 2017

U.S. NDA Submission for Migalastat Planned in 4Q17

Pompe Retrospective and Prospective Data Collection Studies Initiated

Additional Pompe Clinical Data to be Presented at WORLDSymposium in February 2018

CRANBURY, N.J., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company at the forefront of... More